This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Ventas Q1 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q1 results reflect higher same-store cash NOI due to SHOP same-store average occupancy growth.
Ventas (VTR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) Beats Q1 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.44% and 4.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medical Properties in Q1 Earnings?
by Zacks Equity Research
While MPW's Q1 earnings are likely to have benefited from the favorable healthcare industry trends, exposure to certain troubled operators may have hurt it.
SBA Communications Q1 AFFO & Revenues Beat Estimates, '25 View Raised
by Zacks Equity Research
SBAC's Q1 results reflect significant growth in site-development revenues. However, higher costs and interest expenses ail.
Alexandria Q1 AFFO Beats Estimates, 2025 View Lowered
by Zacks Equity Research
ARE's Q1 results reflect decent leasing activity and higher rental rates. However, lower occupancy and higher interest expenses impacted the performance.
Unlocking Q1 Potential of Ventas (VTR): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
What's in the Cards for Brookfield This Earnings Season?
by Zacks Equity Research
Lower rates on its foreign exchange hedge contracts and high interest expenses are likely to have impacted BIP's Q1 results despite its diversified infrastructure assets.
Iron Mountain to Post Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
IRM's Q1 earnings are likely to have been hurt by shifts in data storage through non-paper-based technologies despite solid data center demand.
What's in the Cards for Kimco Realty Stock in Q1 Earnings?
by Zacks Equity Research
KIM's Q1 earnings are likely to have gained from its grocery-anchored, diverse premium properties in high-growth markets and focus on mixed-use assets.
What's in the Offing for Ventas Stock This Earnings Season?
by Zacks Equity Research
While VTR's Q1 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
Healthpeak's Q1 FFO Meets Estimates, Same-Store NOI Rises
by Zacks Equity Research
DOC's Q1 results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
Ventas (VTR) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
W.P. Carey to Report Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
WPC's Q1 results are likely to reflect gains from a high-quality, diverse single-tenant net lease commercial portfolio amid strong demand for industrial assets.
Extra Space Storage to Post Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
EXR's Q1 results are likely to reflect gains from high brand value, a solid presence in key cities and expansionary efforts.
BXP Gears Up to Report Q1 Earnings: Key Factors to Consider
by Zacks Equity Research
BXP's Q1 earnings are likely to have been boosted by healthy demand for premium office assets. However, high competition and interest expenses might have hurt.
Welltower Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
WELL's Q1 earnings are likely to have benefited from the rise in the aging population and its healthcare expenditure. Yet, high interest expenses are a concern.
What's in the Cards for SBA Communications Stock This Earnings Season?
by Zacks Equity Research
SBAC's Q1 earnings are likely to have been affected by ongoing consolidation in the wireless industry and higher churn.
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q1 earnings are likely to have benefited from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Is it Wise to Retain Highwoods Properties Stock in Your Portfolio Now?
by Zacks Equity Research
HIW to gain from rising leasing activity due to high demand for quality office spaces. However, high competition and elevated interest rates are concerns.
Ventas Stock Surges 13.9% in Three Months: Will the Trend Last?
by Zacks Equity Research
Aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio are likely to support VTR.
Zacks Market Edge Highlights: VTR, BRK.B and NFLX
by Zacks Equity Research
VTR, BRK.B and NFLX have been highlighted in this Market Edge article.
Hide Out in These 3 Stocks During Tariff Turbulence
by Tracey Ryniec
Tracey Ryniec, Zacks Senior Stock Strategist, looks for stocks that might offer shelter from the storm.
This is Why Ventas (VTR) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.